Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: A case-control study

British Journal of Dermatology

Volumn 135, Issue 5, 1996, Pages 704-711

  Marghoob, A A ^d   Slade, J ^a,b,c   Kopf, A W ^a,b,c,f   Salopek, T G ^e   Rigel, D S ^a,b,c   Bart, R S ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Skin and Cancer Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0029906869     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb03877.x     Document Type: Article

References (47)

1. Marghoob AA, Kopf AW, Kigel DS et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome: a case-control study. Arch Dermatol 1994; 130: 993-8.
2. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical-mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995; 32: 479-94.
3. McBride A, Rivers JK, Kopf AW et al. Clinical features of dysplastic nevi. Dermatol Clin 1991; 9: 717-22.
4. Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. J Am Acad Dermatol 1990; 22: 117-18.
5. Mackie RM. Multiple melanoma and atypical melanocytic naevi-evidence of an activated and expanded melanocytic system. Br J Dermatol 1982; 107: 621-9.
6. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D, Organic SM. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993; 100: 350-5S.
7. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions: 'The B-K mole syndrome'. Arch Dermatol 1978; 114: 732-8.
8. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102: 458-65.
9. Sigg C, Pelloni K, Schnyder UW. Gehaufte mehrfachmelanome bei sporadischem und familiarem dysplastischen navuszellnavussyndrom. Hautarzt 1989; 40: 548-52.
10. Anderson DE, Smith JL, McBride CM. Hereditary aspects of malignant melanoma. JAMA 1967; 200: 741-6.
11. Carey WP, Thompson CJ, Synnestvedt M et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74: 3118-25.
12. Anderson DE. Clinical characteristics of the genetic variety of cutaneous melanoma in man. Cancer 1971; 28: 721-5.
13. Wallace DC, Beardmore GL, Exton LA. Familial malignant melanoma. Ann Surg 1973; 177: 15-20.
14. Wallace DC, Exton LA, McLeod GRC. Genetic factor in malignant melanoma. Cancer 1971; 27: 1262-6.
15. Halpern AC, Guerry IV D, Elder DE, Trock B, Synnestvedt M. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100: 346-9S.
16. Mackie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993; 341: 1618-20.
17. Lucchina LC, Barnhill RL, Duke DM, Sober AJ. Familial cutaneous melanoma. Melanoma Res 1995; 5: 413-18.
18. Titus-Ernstoff L, Duray PH, Ernstoff MS, Barnhill RL, Horn PL, Kirkwood JM. Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1988; 48: 1016-18.
19. Titus-Ernstoff L, Ernstoff MS, Kirkwood JM, Barnhill RL, Fine J, Duray PH. Usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma. Cancer Detect Prevent 1989; 13: 317-21.
20. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-1980. Natl Cancer Inst Monogr 1985; 68: 361-88.
21. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985; 68: 161-89.
22. Pack GT, Scharnagel IM, Hillyer RA. Multiple primary melanoma. A report of sixteen cases. Cancer 1952; 6: 1110-15.
23. Landthaler M, Braun-Falco O, Bernreiter F, Holzel D. Multiple primare maligne tumoren bei patienten mit malignem melanom der haut. Hautarzt 1992; 43: 11-15.
24. Gupta BK, Piedmonte MR, Karakousis CP. Attributes and survival patterns of multiple primary cutaneous malignant melanomas. Cancer 1991; 67: 1984-9.
25. Kopf AW, Hellman LJ, Rogers GS et al. Familial malignant melanoma. JAMA 1986; 256: 1915-19.
26. McLeod R, Davis NC, Herron JJ et al. A retrospective survey of 498 patients with malignant melanoma. Surg Gynecol Obstet 1968; 1: 99-108.
27. Peterson NC, Bodenham DC, Lloyd OC. Malignant melanomas of the skin. A study of the origin, development, etiology, spread, treatment, and prognosis. Br J Plastic Surg 1962; 15: 49-94.
28. Scheibner A, Milton GW, McCarthy WH, Norlund JJ, Pearson LJ. Multiple primary melanoma - A review of 90 cases. Aust J Dermatol 1982; 23: 1-8.
29. Bellet RE, Vaisman I, Mastrangelo MJ, Lustbader E. Multiple primary malignancies in patients with cutaneous melanoma. Cancer 1977; 40: 1974-81.
30. Slingluff CL, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 1993; 113: 330-9.
31. Kang S, Barnhill RL, Mihm MC, Sober AJ. Multiple primary cutaneous melanomas. Cancer 1992; 70: 1911-16.
32. Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol 1975; 111: 603-9.
33. Veronesi U, Cascinelli N, Bufalino R. Evaluation of the risk of multiple primaries in malignant cutaneous melanoma. Tumori 1976; 62: 127-30.
34. Allen AC, Spitz S. Malignant melanoma. A clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 1953; 6: 1-45.
35. Beardmore GL. The Queensland melanoma project. Int J Dermatol 1977; 10: 831-5.
36. Moseley HS, Giuliano AE, Storm FK III, Clark WH, Robinson DS, Morton DL. Multiple primary melanoma. Cancer 1979; 43: 939-44.
37. Burden AD, Vestey JP, Sirel JM, Aitchison TC, Hunter JAA, MacKie RM. Multiple primary melanoma: risk factors and prognostic implications. Br Med J 1994; 309: 375.
38. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res 1995; 5: 433-8.
39. Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK (eds). Cancer Statistic Review: 1973-1989. NIH Pub. No. 92-2789. Bethesda. MD: National Cancer Institute, 1992.
40. Slue W, Kopf AW, Rivers JK. Total-body photographs of dysplastic nevi. Arch Dermatol 1988; 124: 1239-43.
41. SAS Institute Inc. SAS Procedures Guide. Release 6.03 ed. Cary, NC: SAS Institute Inc. 1988.
42. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699-712.
43. Lee E, Desu M. A computer program for comparing k samples with right-censored data. Comput Methods Programs Biomed 1972; 2: 315-21.
44. Frank W, Rogers GS. Melanoma update. Second primary melanomas. J Dermatol Surg Oncol 1993; 19: 427-30.
45. Marghoob AA, Slade J, Salopek TG et al. Basal-cell and squamous-cell carcinomas are important risk factors for cutaneous malignant melanoma: screening implications. Cancer 1995; 75: 707-14.
46. Rigel DS, Rivers JK, Friedman RJ, Kopf AW. Risk gradient for malignant melanoma in individuals with dysplastic naevi. Lancet 1988; i: 352-3.
47. Rigel DS, Friedman RJ, Kopf AW et al. Importance of complete cutaneous examination for detection of malignant melanoma. J Am Acad Dermatol 1986; 14: 857-60.